The effect of ECMO on the pharmacokinetics of hydromorphone

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200055727

Enrollment

Unknown

Registered

2022-01-16

Start date

2022-02-01

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients treated with ECMO

Interventions

experimental group:hydromorphone

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 18 and 70 years, 18 inclusive; using hydromorphone for pain relief; 2. Using ECMO for more than 48h; 3. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Being allergic to hydromorphone; 2. Using of CRRT during ECMO; 3. Liver function Child-Pugh grade B, C; 4. Pregnancy; 5. Intestinal obstruction.

Design outcomes

Primary

Measure	Time frame
pharmacokinetics;	—

Countries

China

Contacts

Public ContactShang You

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

you_shanghust@163.com+86 15972127819

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026